Clinical Trial

With new Phase 3 data for inactive thyroid eye disease, Innovent Biologics is solidifying a domestic moat against foreign biotech rivals in China.

A landmark 6,000-person trial by Holobiome and Radicle Science is utilizing AI and decentralized testing to see if food can solve anxiety.

By bypassing the blood-brain barrier, AviadoBio's novel gene therapy halts key neurodegeneration markers in a devastating form of genetic dementia.

CytoDyn is pivoting to oncology with its CCR5 inhibitor leronlimab. Upcoming Phase 2 data at ESMO 2026 could determine the biotech's financial survival.

Asahi Kasei Therapeutics begins Phase 2a trials for AIC468, a pioneering RNA-splicing therapy aiming to solve a critical kidney transplant dilemma.

A breakthrough gene therapy restores natural hearing in children, challenging mechanical implants and reshaping the economics of genomic medicine.

With a new $125M Series D, Medical Microinstruments is moving robotics into the sub-millimeter realm, targeting lymphatic repair and Alzheimer's disease.

Alpheus Medical's new clinical trial tackles butterfly glioblastoma, leveraging non-invasive ultrasound and strategic financing to disrupt oncology.

Margaret Mitchell explores how a German biotech's moss-grown protein could shift the paradigm in complement-mediated diseases from inhibition to restoration.

With a $50B market in play, NFL Biosciences is leveraging predictive biomarkers and novel neurobiology to disrupt the stagnant smoking cessation landscape.

Equillium's Phase 1 trial of EQ504 in Australia signals a strategic shift in ulcerative colitis care, prioritizing targeted mucosal healing.

ViroMissile's intravenously delivered oncolytic virus, IDOV-2, shows early signs of stable disease in Phase I, hinting at a breakthrough for metastatic cancers.

Taysha Gene Therapies leverages novel auto-regulatory technology and a strategic regulatory playbook to pioneer a breakthrough gene therapy for Rett syndrome.

As GLP-1 drugs face scrutiny for causing lean tissue loss, advanced MRI biomarkers are reshaping clinical trials and the future of metabolic medicine.

Targeted protein degradation is breaking out of oncology. Monte Rosa’s latest Phase 1 readout tests if molecular glues can solve residual heart disease risk.

Quorum Innovations has published early human data on Qi601, a postbiotic designed to trap microplastics in the gut before they enter human cells.

French biotech EVerZom successfully completes preclinical studies for its exosome-based EVerGel, targeting a 2027 clinical debut for Crohn's disease fistulas.

FastWave Medical's Sola system posts a 96.4% success rate, signaling a high-speed, laser-driven disruption in the multi-billion-dollar lithotripsy market.

As BioAge prepares for major investor conferences, the biotech firm is nearing a critical Phase 2 readout that could redefine cardiometabolic and obesity care.

J&J's CARVYKTI shows half of early-line myeloma patients achieve five-year remissions. But does a functional cure justify the severe upfront risks?